



Freedom of Information Request: Our Reference CTMUHB_364_25

You asked:

I am analysing the treatment of dermatological conditions in the UK. Could you please answer the following questions.

Q1. How many patients were treated in the last 4 months (April to July 2025) by the dermatology department with each of the following products:

- **Abrocitinib**
- **Acitretin**
- **Alitretinoin**
- **Azathioprine**
- **Baricitinib**
- **Ciclosporin**
- **Dupilumab**
- **Lebrikizumab**
- **Methotrexate**
- **Mycophenolate mofetil**
- **Pimecrolimus**
- **Tacrolimus ointment**
- **Tralokinumab**
- **Upadacitinib**
- **Nemolizumab**

- **Phototherapy (UVB or PUVA) - for Atopic Dermatitis only**

Zero (0) - We have been unable to treat any patients for this type of treatment due to replacement equipment on order.

Please find below tables populated with data that is currently available to Medicines Management. Due to the different formats of recorded data across Secondary and Primary Care Sectors we have supplied information by patient numbers where possible. However, where this level of information is not available we have provided information in the format of Number of Issues.

The period the data relates to is the latest 4 months available; Secondary Care 1st April 2025 to 31st July2025 and Primary Care, 1st February 2025 to 31st May 2025.

Secondary Care

Medicine	Number of Patients
Abrocitinib	7

Baricitinib	5
Dupilumab	274
Lebrikizumab	13
Tralokinumab	18
Upadacitinib	14
Nemolizumab	0

Secondary Care

Medicine	Number of Issues
Acitretin	59
ACITRETIN 10 mg Capsules	301
ACITRETIN 25 mg Capsules	53
Alitretinoin	3
ALITRETINOIN 10 mg Capsules	2
ALITRETINOIN 30 mg Capsules	13
AZATHIOPRINE 10 mg in 1mL Oral Suspension Sugar Free	2
CICLOSPORIN 25 mg Capsules	7
CICLOSPORIN 50 mg Capsules	13
CICLOSPORIN 100 mg Capsules	17
Methotrexate	1373
Azathioprine	339
METHOTREXATE (METOJECT) 10 mg in 0.2mL Pre-Filled Pen	37
METHOTREXATE (METOJECT) 12.5 mg in 0.25mL Pre-Filled Pen	8
METHOTREXATE (METOJECT) 15 mg in 0.3mL Pre-Filled Pen	113
METHOTREXATE (METOJECT) 17.5 mg in 0.35mL Pre-Filled Pen	70
METHOTREXATE (METOJECT) 20 mg in 0.4mL Pre-Filled Pen	42
METHOTREXATE (METOJECT) 25 mg in 0.5mL Pre-Filled Pen	37
METHOTREXATE (METOJECT) 7.5 mg in 0.15mL Pre-Filled Pen	18
METHOTREXATE 10 mg in 5mL Oral Solution Sugar Free	2
METHOTREXATE 2.5 mg Tablets	230
MYCOPHENOLATE MOFETIL (CELLCEPT) 500 mg Tablets	10
PIMECROLIMUS 1 % Cream	2
TACROLIMUS 0.1 % Ointment	10
Tacrolimus_Oint 0.03%	5

Primary Care

Medicine	Number of Issues
Methotrexate	4976
Azathioprine	1098
Mycophenolate	469
Pimecrolimus_Crm 1%	47
Tacrolimus_Oint 0.1%	208
Tacrolimus_Oint 0.03%	52
Acitretin	6

Q2. In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department

- **Abrocitinib**
- **Baricitinib**
- **Dupilumab**
- **Lebrikizumab**
- **Tralokinumab**
- **Upadacitinib**
- **Nemolizumab**

***Patients are considered initiated on a treatment if they have not been treated with the named treatment in the previous 8 months.**

Secondary Care

Medicine	Number of Patients
Abrocitinib	0
Baricitinib	0
Dupilumab	35
Lebrikizumab	**
Tralokinumab	5
Upadacitinib	5
Nemolizumab	0

Where the patient numbers are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Q3. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:

- **6 months to 5**
- **Age 6-11**
- **Age 12-17**
- **Age 18 and above**

We do not centrally record this information. Patient level details are not captured on our Medicines Management system. Therefore, we are unable to provide the number of patients by age group.

The detailed information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.